Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27791244 | 1.00 | EPHX1 (0.51) | EPHX1GAASMN1; SMN2CACNA1BBTK | |
| SCHEMBL26043772 | 0.98 | EPHX1 (0.49) | EPHX1GAASMN1; SMN2CACNA1BBTK | |
| SCHEMBL27813335 | 0.95 | BTK (0.45) | EPHX1GAASMN1; SMN2CACNA1BBTK | |
| SCHEMBL21197505 | 0.91 | NFKB1 (0.41) | EPHX1GAACACNA1BBTKALDH1A1 | |
| SCHEMBL3068442 | 0.84 | EPHX1 (0.65) | EPHX1SMN1; SMN2NPC1HTTRAB9A | |
| SCHEMBL6498943 | 0.81 | BTK (0.35) | EPHX1GAASMN1; SMN2CACNA1BBTK | |
| SCHEMBL5283279 | 0.78 | EPHX1 (0.52) | EPHX1GAACACNA1BHTTALDH1A1 | |
| SCHEMBL1079567 | 0.78 | EPHX1 (0.46) | EPHX1GAASMN1; SMN2CACNA1BBTK | |
| SCHEMBL28161422 | 0.77 | GAA (0.53) | EPHX1GAASMN1; SMN2BTKNPC1 | |
| SCHEMBL11593346 | 0.77 | EPHX1 (0.44) | EPHX1GAASMN1; SMN2CACNA1BNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009132452-A1 | DIARYL-CYCLYLALKYL DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-11-05 | — | — | WO | disclosed |
| US-20090270338-A1 | DIARYL-CYCLYLALKYL DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270338-A1 | DIARYL-CYCLYLALKYL DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | EPHX1 3500/4885GAA 2152/4885SMN1; SMN2 3290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.